Speculative buy on Bluebird Bio (BLUE)...

[njfan47]

This company is using gene therapy treatment, rather than the traditional chemotherapy and radiation to treat cancer. Currently, they are working with Celgene in a Phase 1 clinical study, so it's very early, but they are clearly onto something. The stock is not cheap at $106, and is for speculative accounts only, at this time, but it could be a big winner and takeover candidate.

 

[njfan47]

Bluebird Bio was up $12 today to $125, so we've got an 18% gain in two months. No specific news on the company, but another company who develops CAR-T (chimeric antigen receptor t-cell) therapies, Novartis, had its therapy approved by the FDA earlier this week.

Both companies are still working to develop a drug to treat Trump Derangement Syndrome, although several professionals have recommended counseling instead. Others hope that the deranged liberals don't get either counseling or a drug, as the entertainment value on this board might disappear.

 

[njfan47]

Bluebird Bio (BLUE) is now up to $165. Stock is up 55% in the 5+ months since the original recommendation. Continue to hold the stock. I hope samuel and reluctant didn't buy the stock. In fact, I'd be shocked if they did.

 

[Stalker]

Don't you love this Bull Market. Even Democrats can make money in this market,. That was a joke guys.

 

[njfan47]

Bluebird Bio is up $40 today to $211. While the 23% one-day gain makes it tempting to take profits, it's best to still hold on. A phase one trial of Bluebird's CAR-T drug (bb2121) was effective on 17 of 18 patients who had advanced multiple myeloma, a blood cancer. Seven of the patients were considered to have been complete responders, meaning that all signs of cancer disappeared.

Bluebird could be a very good takeover candidate; the leading suitor might be its partner in bb2121, Celgene. With Bluebird having a current market cap of $10 billion, maybe $15 billion in a takeover, $85 billion Celgene could be in a position to do the deal, but maybe Pfizer or Merck get involved too.

 

[njfan47]

Bluebird Bio corrected today, closing at $190.95. At this level, it's a buy, but with the understanding that the above-mentioned testing is phase one of the three that are needed in order to achieve commercialization.

 

[njfan47]

Not to monopolize the board with Bluebird, but the latest news is that they are going to do a secondary stock offering of 3.2 million shares at $185. That has pushed the price down to a low of $181 this morning and $182 right now. This dilutes potential earnings, but it's not a big issue. And, on the positive side, it gives the company more working capital. Buy more.

 

[njfan47]

Update: Bluebird has bounced back to $213 as of today. Liberals on this board think the market is crashing (talk about delusional), but stocks like Bluebird continue to move forward and is now up 100% from the recommendation made in late June 2017. We know that Sammy didn't buy because he's "not in the stock market."

 

[njfan47]

Bluebird Bio closed at $231.95 on Friday, up $6.00 vs. Thursday's close. Continue to hold in spite of 119% gain in nine months. There could still be a takeover although the company now has a market capitalization of $11.6 billion, so it would be a lot to take on.